Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
Maurie Markman, MD, president of medicine and science at the Cancer Treatment Centers of America, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
For example, Markman says that the development of platinum-based chemotherapies such as paclitaxel started in ovarian cancer. Over time, this development became increasingly important in other cancers and tumor types as well.
Five years ago, treatments from ovarian cancer were not being used in areas such as lung cancer, but currently, these effective chemotherapies, targeted therapies, and immunotherapies are being used in a number of cancer types for chronic management, Markman adds.
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More